Animal models in psychiatry

Teixeira, Antônio Lúcio; Quevedo, Joao L De

doi:10.1590/1516-4446-2013-1182

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animal models remain a mainstay to investigate neurobiological mechanisms underlying complex mood disorders such as mania (Machado-Vieira et al, 2004b; Teixeira and Quevedo, 2013; Valvassori et al, 2013; Young et al, 2011a). Likewise, animal models for mania are considered a valuable tool for the screening of new agents with mood stabilizing properties (Armani et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…While behavioral responses, such as fear, aggressiveness, irritability, euphoria, and dysphoria may be regarded as subjective components of mania, other manifestations such as locomotor activity and aberrations in circadian rhythms may be considered objective manic-like behaviors. Likewise, other physiological responses may also be measured in preclinical models of mania providing insights on molecular and cellular pathophysiological processes involved in the genesis, persistence, and treatment of BD in humans (Teixeira and Quevedo, 2013; Valvassori et al, 2013; Young et al, 2011a). Recently, the field has witnessed significant advances with the development of novel preclinical models of mania (Dzirasa et al, 2011; Einat, 2014a; Sidor et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modeling mania in preclinical settings: A comprehensive review

Sharma

Fries

Gálvez

et al. 2016

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

The current pathophysiological understanding of mechanisms leading to onset and progression of bipolar manic episodes remains limited. At the same time, available animal models for mania have limited face, construct, and predictive validities. Additionally, these models fail to encompass recent pathophysiological frameworks of bipolar disorder (BD), e.g. neuroprogression. Therefore, there is a need to search for novel preclinical models for mania that could comprehensively address these limitations. Herein we review the history, validity, and caveats of currently available animal models for mania. We also review new genetic models for mania, namely knockout mice for genes involved in neurotransmission, synapse formation, and intracellular signaling pathways. Furthermore, we review recent trends in preclinical models for mania that may aid in the comprehension of mechanisms underlying the neuroprogressive and recurring nature of BD. In conclusion, the validity of animal models for mania remains limited. Nevertheless, novel (e.g. genetic) animal models as well as adaptation of existing paradigms hold promise.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Modeling mania in preclinical settings: A comprehensive review

Sharma

Fries

Gálvez

et al. 2016

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

Animal Models of Mania: Essential Tools to Better Understand Bipolar Disorder

Miranda

Andreatini

Teixeira

2017

Animal Models for the Study of Human Disease

View full text Add to dashboard Cite

Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review

Shore,

Dobson,

Thomson

et al. 2024

Preprint

View full text Add to dashboard Cite

Background and Aims: Psilocybin is a psychedelic drug that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review on pre-clinical behavioural investigations of psilocybin in non-human animals to help determine the behavioural effects of psilocybin in non-human animals, to identify studies completed, behavioural tests employed, and what dosing modalities had been studied. Methods: A librarian-conducted literature search was performed using predefined key terms and search criteria and additional searching was conducted by reviewers, using electronic databases, grey literature sources, and reference lists of relevant articles or reviews. The final search updated occurred in October, 2021. Studies were reviewed, screened and selected against an a priori protocol using Covidence software by multiple reviewers with results plotted across the Research Domains Criteria construct. Results: From 4124 records identified by database searching, 260 publications were subjected to full-text review with 77 studies included in this scoping review, published between 1962-2021. The preponderance of studies (n=64) investigated behavioural outcomes in rodents. Only 43 studies (55.8%) reported on housing conditions, and seventeen studies (22.1%) failed to report sample size. All studies reported behavioural outcomes following drug administration, with fifty-one studies (66.2%) using psilocybin, thirty studies (42.9%) psilocin, four studies (5.2%) administering whole mushroom extracts (WME), and a further eight studies investigating both psilocybin and psilocin and one study reporting the effects of both psilocin and WME. One hundred and thirty distinct behavioural investigations using fifty different behavioral paradigms were identified. Few adverse events were reported, and even exceedingly high doses were apparently well tolerated. Conclusion: With seventy-seven publications spanning close to sixty years, there is huge variation in study design and quality. Overall psilocybin presents a unique and strong safety profile with no evidence of biological toxicity, is characterized by unique time and dose-dependent effects, and its pattern of drug action is significantly context and training-sensitive. Data suggest putative effects of psilocybin include acute arousal, dose-dependent sedation, reductions in fear conditioning at low doses, reduced aggression, improved valence, acute disruption of working memory, the rescuing of deficits from chronic stress, and improved learning when combined with repeated environmental exposure after resolution of drug effect. Keywords: psilocybin, psychedelic, non-human animal research, scoping review, behavioural research, Research Domains Criteria.

show abstract

Animal models in psychiatry

Cited by 3 publications

References 14 publications

Modeling mania in preclinical settings: A comprehensive review

Modeling mania in preclinical settings: A comprehensive review

Animal Models of Mania: Essential Tools to Better Understand Bipolar Disorder

Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review

Contact Info

Product

Resources

About